Wellgistics Health, Inc.

WGRX Nasdaq CIK: 0002030763

Company Information

Industry Wholesale-Drugs, Proprietaries & Druggists' Sundries
SIC Code 5122
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 3000 BAYPORT DRIVE SUITE 950, TAMPA, FL, 33607
Mailing Address 3000 BAYPORT DRIVE SUITE 950, TAMPA, FL, 33607
Phone 1-843-302-1785
Fiscal Year End 1231
EIN 933264234

Financial Overview

FY2024

$-0.06
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events February 13, 2026 View on SEC
8-K Current report of material events February 9, 2026 View on SEC
8-K Current report of material events February 5, 2026 View on SEC
8-K Current report of material events January 20, 2026 View on SEC
8-K Current report of material events January 8, 2026 View on SEC
8-K Current report of material events December 19, 2025 View on SEC
8-K Current report of material events December 16, 2025 View on SEC
8-K Current report of material events December 8, 2025 View on SEC
8-K Current report of material events December 5, 2025 View on SEC
8-K/A Current report amendment November 26, 2025 View on SEC

Material Events

8-K Strategy Change February 13, 2026
High Impact
  • Wellgistics resolves over $10.7 million in liabilities, significantly improving its balance sheet and reducing financial risk.
  • New consulting Chief Business Officer, Gerald Commissiong, appointed to strengthen leadership and drive strategic growth initiatives.
View Analysis
8-K Financial Distress December 16, 2025
High Impact
  • Wellgistics Health received a serious warning from Nasdaq for its stock price being below $1.00 for 30 consecutive business days.
  • The company is at risk of being delisted from Nasdaq if it fails to regain compliance.
View Analysis

Related Companies

Companies in the same industry (SIC: 5122)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.